Every Form 4 that CYTODYN INC (CYDY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CYDY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYDY filings page.
CytoDyn Inc. director Tanya Durkee Urbach received a grant of non-qualified stock options covering 574,385 shares of common stock at an exercise price of $0.2800 per share. The grant was approved by the Compensation Committee on March 20, 2026, as her annual fiscal 2026 award under CytoDyn's 2012 Equity Incentive Plan.
The options vest in 12 approximately equal monthly installments from April 2026 through March 2027, contingent on continued service. Following this grant, Urbach holds stock options for 574,385 underlying shares directly.
CytoDyn Inc. director Stephen M. Simes received a grant of 574,385 non-qualified stock options to buy common stock at $0.28 per share. The award was approved on March 20, 2026 as his regular annual grant under CytoDyn’s 2012 Equity Incentive Plan.
The options expire on March 20, 2036 and vest in 12 approximately equal monthly installments from April 2026 through March 2027, contingent on his continued service. Following this grant, Simes holds 574,385 derivative securities representing the right to acquire the same number of common shares.
CytoDyn Inc. director Lishomwa C. Ndhlovu received a non-qualified stock option grant covering 574,385 shares of common stock at an exercise price of $0.28 per share. The option expires on March 20, 2036 and was approved as the annual grant for fiscal year 2026 under CytoDyn's 2012 Equity Incentive Plan.
The award vests in 12 approximately equal monthly installments for continuous service from April 2026 through March 2027. After this grant, Ndhlovu holds stock options for 574,385 shares directly.
CytoDyn Inc. reported that Chief Executive Officer Jacob P. Lalezari received a grant of non-qualified stock options for 4,874,691.0000 shares of common stock at an exercise price of $0.2800 per share as his annual fiscal 2026 award under the 2012 Equity Incentive Plan.
According to the vesting schedule, 1,218,672 underlying shares will vest on March 20, 2027, with the remaining options vesting in approximately equal monthly installments from April 2027 through March 2030, subject to continuous service. This is a compensation-related, non-market transaction.
CytoDyn Inc. reported that Chief Financial Officer Robert E. Hoffman received a grant of non-qualified stock options covering 4,874,691 shares of common stock. The options have an exercise price of $0.28 per share and expire on March 20, 2036.
This award represents his annual equity grant for fiscal year 2026 under CytoDyn's 2012 Equity Incentive Plan. Vesting is time-based: 1,218,672 shares vest on March 20, 2027, with the remaining options vesting in approximately equal monthly installments from April 2027 through March 2030, contingent on continued service.
CytoDyn Inc. director Dunlap Ryan reported receiving a grant of non-qualified stock options to buy 574,385 shares of common stock. The options have an exercise price of $0.28 per share and expire in March 2036. This award represents his annual fiscal 2026 grant under CytoDyn's 2012 Equity Incentive Plan.
The options vest in 12 approximately equal monthly installments from April 2026 through March 2027, conditioned on continued service. After this grant, Ryan holds 574,385 derivative securities, and the filing does not show any open-market purchases or sales of CytoDyn common stock.
CytoDyn Inc. director Karen J. Brunke received a grant of non-qualified stock options covering 574,385 shares of common stock. The options have an exercise price of $0.28 per share and were approved as her annual fiscal 2026 grant under CytoDyn's 2012 Equity Incentive Plan.
The award vests in 12 approximately equal monthly installments from April 2026 through March 2027, subject to continuous service. Following this grant, Brunke holds 574,385 derivative securities in the form of these options directly.
CytoDyn Inc. reported that Chief Legal Officer Tyler Blok received a grant of non-qualified stock options as part of his fiscal 2026 compensation. The award covers 3,249,794 options to buy common stock at an exercise price of $0.28 per share, expiring in 2036.
The grant was approved by the Compensation Committee on March 20, 2026 under CytoDyn’s 2012 Equity Incentive Plan. 812,448 underlying shares will vest on March 20, 2027, with the remaining options vesting in roughly equal monthly installments from April 2027 through March 2030, subject to continuous service.